skills/sector-analysis/references/modules/M100-biotechnology-analyst-playbook.md

<!-- Generated loss-aware reference mirror from God_Level_Public_Company_Financial_Analyst_Job_Guide_V6_99_ALL_SUB70_FIXED.docx. Canonical source remains the bundled DOCX. -->

<!-- Module: 100 | Title: Biotechnology Analyst Playbook -->

## PART XV - SECTOR PLAYBOOKS | MODULE 100

# Biotechnology Analyst Playbook

> Mission. Build a sector-specific research system for Biotechnology that converts operating data into financial outcomes, highlights the accounting areas most likely to distort comparability, and selects valuation methods that reflect the sector's economics.

## Economic engine and binding constraints

Build probability-adjusted program value by indication, phase, addressable patients, price, probability of technical/regulatory success, timeline, dilution, partnership economics, and cash runway. Use scenario trees, not a single success probability.

## Primary KPI stack

| KPI | Construction / analyst control |
| --- | --- |
| cash runway | Unrestricted cash and marketable securities divided by forecast monthly/quarterly net cash burn after committed financings and milestone payments. Validation: Tie cash, debt, facilities, maturities, and fixed charges to balance-sheet/footnote data; stress availability restrictions, refinancing assumptions, and downside cash generation. |
| trial enrollment | Patients enrolled or randomized divided by target enrollment and elapsed enrollment time; track sites activated and enrollment rate per site. Validation: Recalculate independently from cited source data; verify definition, period, units, scope, signs, and any reconciliation to reported financial or operating totals. |
| endpoints | DPO = average accounts payable / COGS x days in period |
| probability of success | Probability that an asset advances from its current development stage to approval/commercial success, using stage-specific base rates adjusted for asset evidence. Validation: Document scenario definitions and probabilities; verify probabilities sum appropriately, inputs are independently sourced, and sensitivity is recomputed rather than manually overridden. |
| cash burn | Cash operating and investing outflows less recurring cash inflows over the period, excluding financing inflows; use a normalized forward burn rate. Validation: Tie cash, debt, facilities, maturities, and fixed charges to balance-sheet/footnote data; stress availability restrictions, refinancing assumptions, and downside cash generation. |
| dilution | Net dilution = ending diluted share count / beginning diluted share count - 1, adjusted for major capital actions |
| partner economics | Company share of economics from partnered assets, including upfronts, milestones, cost sharing, royalties, profit splits, and commercialization obligations. Validation: Recalculate independently from cited source data; verify definition, period, units, scope, signs, and any reconciliation to reported financial or operating totals. |
| launch readiness | Weighted completion of manufacturing, regulatory, payer, distribution, commercial, and field-force milestones required for launch by the planned date. Validation: Recalculate independently from cited source data; verify definition, period, units, scope, signs, and any reconciliation to reported financial or operating totals. |



## Sector-specific accounting and comparability traps

- R&d expense: reconcile issuer treatment with peer treatment and quantify the effect on reported growth, margin, cash flow, capital, or valuation before comparing outputs.

- Milestone recognition: reconcile issuer treatment with peer treatment and quantify the effect on reported growth, margin, cash flow, capital, or valuation before comparing outputs.

- Warrants: reconcile issuer treatment with peer treatment and quantify the effect on reported growth, margin, cash flow, capital, or valuation before comparing outputs.

- Convertibles: reconcile issuer treatment with peer treatment and quantify the effect on reported growth, margin, cash flow, capital, or valuation before comparing outputs.

- Going concern: reconcile issuer treatment with peer treatment and quantify the effect on reported growth, margin, cash flow, capital, or valuation before comparing outputs.

## Valuation frameworks

- Risk-adjusted NPV: probability-weight each asset/project cash flow by technical/regulatory/commercial success, discount by timing/risk, and subtract remaining development/funding costs.

- Cash plus pipeline value: unrestricted net cash plus probability-weighted NPV of pipeline assets minus remaining R&D, corporate burn, milestone obligations, and dilution/funding needs.

- Scenario valuation: assign internally consistent operating and financing cases, value each case independently, and probability-weight only after defining mutually exclusive outcomes and thesis-break states.

## Sector diligence questions

- What is the most important leading indicator for Biotechnology, and how many months does it lead reported revenue or cash flow?

## Sector stress and falsification

- Stress cash runway and trial enrollment together in the direction most likely to break the equity story; flow the result through working capital, capex, liquidity, financing, dilution, and valuation.

- Explicitly test R&D expense. Determine whether it can make the reported sector comparison look better or worse without equivalent economic change.

## 99-point standalone execution extension

### Model architecture and forecast chain

Model patient population, diagnosis, eligible share, penetration, price, persistence, trial probability, launch timing, cash burn, and financing.

### Leading-indicator dashboard

Track enrollment, trial timelines, biomarker data, regulatory interactions, competitor readouts, manufacturing readiness, KOL adoption, and cash runway.

### Primary-source map

SEC filings; ClinicalTrials.gov; FDA meeting/approval documents and labels; peer scientific publications; patent records; financing and cash-runway disclosures.

### Accounting normalization test

R&D expense, acquired IPR&D, milestone payments, collaboration accounting, warrant/convertible dilution, and going-concern risk dominate.

### Valuation implementation

Use probability-adjusted product DCF/SOTP and explicit financing dilution. Avoid revenue multiples without clinical and capital path.

### Worked numerical mini-case

> Illustrative rNPV case.

A program has $2.0bn peak sales potential, 60% operating margin, 35% probability of approval and four years to launch. Probability-adjust cash flows and subtract expected R&D plus future financing dilution; do not multiply peak sales by probability.

Cash runway and next catalyst timing are part of intrinsic value because financing can change ownership before clinical success is known.

### Monitoring and falsification cadence

Breaks include trial failure, safety, regulatory delay, financing shortfall, competing therapy superiority, or commercial adoption below the required patient share.

At every quarterly update, rebuild the driver bridge from operating units to revenue, margin, cash flow and valuation; compare leading indicators with the prior forecast; record definition changes; and precommit the threshold that would trigger a thesis reset rather than a cosmetic estimate change.

## Sector exit standard

The Biotechnology work is complete only when the analyst can explain the business in its native operating units, reproduce the KPI history, identify the binding growth constraint and marginal price setter, normalize sector-specific accounting, quantify a coherent adverse case, and translate the current market price into the operating expectations that must be met or exceeded.